Get the Stockscreener App
5.64
0.18%
0.010
Verrica Pharmaceuticals Inc stock is traded at $5.64, with a volume of 13,649.
It is up +0.18% in the last 24 hours and down -6.16% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$5.63
Open:
$5.58
24h Volume:
13,649
Relative Volume:
0.30
Market Cap:
$52.07M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-3.8367
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
-14.67%
1M Performance:
-6.16%
6M Performance:
-12.91%
1Y Performance:
-91.09%
1-Day Range:
$5.29
$5.7173
1-Week Range:
$5.29
$7.125
52-Week Range:
$3.816
$62.10
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.64 | 52.07M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
How many analysts rate Verrica Pharmaceuticals Inc. as a “Buy”Beginner Investor Insights That Work - jammulinksnews.com
What makes Verrica Pharmaceuticals Inc. stock price move sharplyFree Capital Efficiency Optimized Stock Alerts - Newser
What does recent volatility data suggest for Verrica Pharmaceuticals Inc.Minimal Risk Growth Investment Opportunity Analysis - Newser
Leading vs lagging indicators on Verrica Pharmaceuticals Inc. performanceFree Multi-Bagger Potential Stock Forecast Tools - Newser
Market reaction to Verrica Pharmaceuticals Inc.’s recent newsSafe Investment Ideas with Growth Upside - Newser
Can machine learning forecast Verrica Pharmaceuticals Inc. recoveryAlgorithmic Prediction of Market Breakouts - Newser
Real time social sentiment graph for Verrica Pharmaceuticals Inc.Swing Setup With Technical Confirmation Explained - metal.it
Is Verrica Pharmaceuticals Inc. forming a bottoming baseTechnical Trade Plan with Entry Checklist - Newser
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attentionTrading Watchlist with Real Time Filters - Newser
MACD Signals Flash Warning for Verrica Pharmaceuticals Inc. StockConsistent Income Focused Trade List Analyzed - beatles.ru
What are the technical indicators suggesting about Verrica Pharmaceuticals Inc.High-octane gains - jammulinksnews.com
What are Verrica Pharmaceuticals Inc. company’s key revenue driversCapital growth strategies that work - jammulinksnews.com
What are analysts’ price targets for Verrica Pharmaceuticals Inc. in the next 12 monthsFree Stock Selection - jammulinksnews.com
Should I hold or sell Verrica Pharmaceuticals Inc. stock in 2025Harness the power of proven investment plans - jammulinksnews.com
Is Verrica Pharmaceuticals Inc. a growth stock or a value stockFree Stock Movement Tracking - jammulinksnews.com
How volatile is Verrica Pharmaceuticals Inc. stock compared to the marketAchieve exceptional returns with expert guidance - jammulinksnews.com
Why is Verrica Pharmaceuticals Inc. stock attracting strong analyst attentionDiscover high-return stocks for your portfolio - jammulinksnews.com
How does Verrica Pharmaceuticals Inc. compare to its industry peersInvest smarter with daily market updates - jammulinksnews.com
Verrica Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayPredictable Return Stock Picks - Newser
How Interest Rate Changes Impact Verrica Pharmaceuticals Inc. Stock PerformanceDaily Trade Opportunity - Newser
Is Verrica Pharmaceuticals Inc. stock overhyped or has real potentialFree Stock Portfolio Optimization - Newser
What analysts say about Verrica Pharmaceuticals Inc. stockExceptional return forecasts - PrintWeekIndia
What drives Verrica Pharmaceuticals Inc. stock priceFree Stock Selection - PrintWeekIndia
VRCA Trading Halted: Anticipation Builds for Pending Announcemen - GuruFocus
Is Verrica Pharmaceuticals Inc. stock a good hedge against inflationRemarkably fast returns - jammulinksnews.com
Verrica Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit velocity - Autocar Professional
Verrica Pharmaceuticals To Carry Out 1-for-10 Reverse Stock Split On July 25th, 2025 - 富途牛牛
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split By Investing.com - Investing.com India
Verrica Pharmaceuticals Announces Reverse Stock Split - TipRanks
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split - Investing.com
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):